Gland Pharma Share Price Jumps to a 52-Week High Despite the Market Sell-Off: Q2 FY27 Profit, CDMO Growth and What to Check
- November 9, 2026
- Posted by: Chaitanya Auti
- Category: News
Gland Pharma jumped about 7% to a 52-week high on 9 Nov 2026 (Mint). Q2 FY27 PAT Rs 290.8 crore, up 58%; revenue Rs 1,833.6 crore, up 23%; EBITDA margin 26%.
Quick Answer
The Gland Pharma share price jumped about 7% to a 52-week high on 9 November 2026, according to Mint, after Q2 FY27 profit rose 58% to Rs 290.8 crore and revenue grew 23% to Rs 1,833.6 crore. The rally came despite a weak market, though valuation, a sequential profit dip and a CEO change are worth checking.
The Gland Pharma share price jumped about 7% to a 52-week high on 9 November 2026 after the company reported a 58% rise in Q2 FY27 profit. This article covers what the results show, what drove the quarter, how the valuation looks after the rally and what to check before reacting. Figures are attributed and time-stamped, and I have no live quote, so verify the current price on NSE or BSE.
Click Here – Get Free Investment Predictions
Gland Pharma Share Price Today: What Moved the Stock to a 52-Week High
| Gland Pharma share price: item | Reading | Source |
|---|---|---|
| Move reported | Up about 7% to a 52-week high, despite a weak market | Mint headline, 9 November 2026 |
| Open and previous close in the Mint stock widget | Opened at Rs 3,147 against a previous close of Rs 3,132.80 | Mint widget as captured |
| Close on 6 November | Rs 3,169.30, up 0.77% | 5paisa data page |
| 52-week range before the move | Rs 1,574 to Rs 3,209 | 5paisa data page |
| Trigger | Q2 FY27 results declared after market hours on 6 November | Company filing and press reports |
The widget price and the 5paisa close differ because they were captured from different pages at different times, so treat each as a snapshot of the Gland Pharma share price rather than a final print. I have no live index data for the session, so check the Nifty 50 and Sensex pages for the market backdrop that Mint describes as a sell-off.
Gland Pharma Q2 FY27 Results: The Numbers Behind the 52-Week High
| Gland Pharma Q2 FY27 results: metric | Q2 FY27 | Q2 FY26 | Change |
|---|---|---|---|
| Revenue | Rs 1,833.6 crore | Rs 1,486.9 crore | Up 23% |
| Net profit (PAT) | Rs 290.8 crore | Rs 183.7 crore | Up 58% |
| EBITDA margin | 26% | 21% | Up about 5 points (my arithmetic) |
| Operating profit | Rs 484.04 crore | Not stated in my sources | Up 54.2% |
| Profit before tax | Rs 430.9 crore | Not stated in my sources | Up 52% |
| R&D spend | Rs 107.7 crore | Not stated in my sources | About 6% of revenue |
| CDMO revenue | Rs 8,227 million, or Rs 822.7 crore (my conversion) | Not stated in my sources | Up 31% |
For the first half, revenue was Rs 3,633.9 crore, up 21%, and PAT rose 52% to Rs 6,077 million, or about Rs 607.7 crore. One detail the headline does not show: Q1 FY27 PAT was Rs 316.96 crore, so Q2 profit of Rs 290.8 crore was about 8.3% lower than the previous quarter (my arithmetic). Revenue was up about 1.9% on Q1’s Rs 1,800.27 crore. The year-on-year jump is real, but the sequential picture is flatter.
Screen pharma stocks by profit growth on the Univest Screener
Gland Pharma 52-Week High: CDMO Growth, USFDA Audits and the CEO Change
| Driver behind the Gland Pharma share price | Detail | Status |
|---|---|---|
| CDMO growth | Revenue up 31% to Rs 8,227 million | Reported |
| Margin expansion | EBITDA margin 26% against 21% a year earlier | Reported |
| Regulatory record | Two facilities audited by the USFDA, one with zero observations | Reported |
| Leadership | Deepak Sapra takes charge as CEO on 16 November 2026; Shyamakant Giri stepped down on 30 April 2026 | Reported |
| Brokerage view | Nomura raised its EPS estimates and expects a 25x to 30x multiple | Reported; target price not in my sources |
Margin expansion on higher CDMO mix is the main operating story behind the 52-week high. A new CEO taking charge a week from now adds a transition variable, which could be positive or neutral; that is my reading, not a company statement. Nomura’s multiple range is an analyst view and not a Univest forecast.
Download the Univest iOS App or Univest Android App to track pharma stocks and alerts.
Gland Pharma Share Price Valuation After the Rally
| Valuation check on the Gland Pharma share price | Reading | Source and date |
|---|---|---|
| Market capitalisation | About Rs 52,297 crore | 5paisa, 6 November |
| P/E and P/B | 42.3 and 4.9 | 5paisa, 6 November |
| 50, 100 and 200-day averages | Rs 2,947.90, Rs 2,755.10 and Rs 2,471.00 | 5paisa, 6 November |
| Price against the 200-day average | About 28% above (Rs 3,169.30 against Rs 2,471.00) | My arithmetic |
| Net worth and ROE | Rs 10,685.7 crore and 11% | Company data via 5paisa |
| One-month change | Up 5.43% | 5paisa, 6 November |
A P/E above 40 with an ROE of 11% leaves less room for disappointment, which is why the Gland Pharma share price can react sharply to the next result or regulatory update. The stock trading well above its 200-day average is a feature of strong momentum, not a statement about value.
What to Check Before Acting on the Gland Pharma Share Price Move
| Check | Why it matters |
|---|---|
| Closing price and volume | An intraday spike to a 52-week high can fade by the close |
| Sequential profit trend behind the Gland Pharma share price 52-week high | Q2 PAT was below Q1, so the year-on-year growth needs context |
| CDMO order flow behind the Gland Pharma 52-week high | The mix shift drives the margin story |
| CEO transition from 16 November and the Gland Pharma share price | Strategy continuity is a risk to monitor |
| Valuation versus growth at a 52-week high | P/E of 42.3 needs sustained earnings growth |
Conclusion
The Gland Pharma share price reached a 52-week high because Q2 FY27 profit rose 58%, margins widened to 26% and CDMO revenue grew 31%. The quarter was softer than Q1 on profit and the valuation is not low, so the rally already reflects good news. Check the close, read the earnings call and consult a SEBI-registered adviser before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on the Gland Pharma Share Price
Why did the Gland Pharma share price hit a 52-week high?
Ans. Mint reported that the shares rose about 7% to a 52-week high after Q2 FY27 results showed PAT up 58% to Rs 290.8 crore, revenue up 23% to Rs 1,833.6 crore and an EBITDA margin of 26% against 21%. The results were declared after market hours on 6 November, so 9 November was the first session to price them in.
What were Gland Pharma's Q2 FY27 results behind the Gland Pharma share price rise?
Ans. Revenue was Rs 1,833.6 crore against Rs 1,486.9 crore, PAT was Rs 290.8 crore against Rs 183.7 crore, operating profit was Rs 484.04 crore, up 54.2%, and PBT was Rs 430.9 crore, up 52%. R&D spend was Rs 107.7 crore, about 6% of revenue.
Did Gland Pharma's profit fall from the previous quarter before the 52-week high?
Ans. Yes. Q1 FY27 PAT was Rs 316.96 crore, so Q2 PAT of Rs 290.8 crore was about 8.3% lower on a sequential basis, by my arithmetic. Revenue rose about 1.9% from Rs 1,800.27 crore. Year-on-year growth remains strong because Q2 FY26 PAT was only Rs 183.7 crore.
Who is the new CEO of Gland Pharma after the 52-week high?
Ans. Deepak Sapra takes charge as CEO on 16 November 2026. Shyamakant Giri stepped down on 30 April 2026. Leadership changes can affect strategy and investor sentiment, so management commentary after the handover is worth following.
What is the 52-week range of the Gland Pharma share price?
Ans. 5paisa showed a 52-week low of Rs 1,574 and a high of Rs 3,209 as of 6 November 2026. A move to a new 52-week high means the stock traded above that Rs 3,209 level, so check a live quote for the current range.
What is the valuation of Gland Pharma after the rally?
Ans. 5paisa data from 6 November showed a market capitalisation of about Rs 52,297 crore, a P/E of 42.3 and a P/B of 4.9, with ROE at 11%. The stock was about 28% above its 200-day average, by my arithmetic. These are pre-rally figures for the 9 November move.
What do analysts say about the Gland Pharma share price?
Ans. Nomura raised its EPS estimates and expects a 25x to 30x multiple, per the reports I reviewed. I did not find a verified target price, so none is quoted. Analyst views differ and are not a forecast by Univest.
Should I buy Gland Pharma shares at a 52-week high?
Ans. Univest cannot give personal advice and does not recommend any security. A 52-week high reflects momentum, not value, and the P/E is above 40. Review the results, valuation and your risk tolerance, and consult a SEBI-registered adviser.